Legal status & 2026 research
Ibogaine has moved from the fringe into statute books and funded trials — and the paperwork keeps switching between plant, salt, and program names.
In the United States, ibogaine has been a Schedule I substance since 1970, meaning it is treated as having no accepted medical use in that framework and is not an approved medicine. Legal status varies internationally, and for years people have travelled to clinics abroad — largely in Mexico — where the words “iboga,” “ibogaine,” and “ibogaine HCl” are often used loosely.
What changed in 2026
On 18 April 2026, a US executive order directed the FDA to prioritise review of psychedelic compounds — ibogaine among them — instructed agencies to ease research restrictions, and committed federal funding to match state programs. It did not reclassify ibogaine.
Texas moved fastest: 2025 legislation created a publicly funded ibogaine research consortium, with the state ultimately backing a program reported at up to $100 million and enrolling on the order of 300 participants — primarily veterans and first responders — under mandatory cardiac screening. In July 2026, the Departments of Veterans Affairs and Health and Human Services signed an agreement to expand coordinated psychedelic research.
Much of that momentum centres on veterans with traumatic brain injury and PTSD, following a 2024 study of thirty veterans that reported improvements a month after treatment. Coverage of ibogaine treatment for veterans is now a major driver of public interest — and a reminder that a statute funding “ibogaine,” a clinic advertising “iboga,” and a trial dosing “ibogaine HCl” are not always describing the same thing.
Legal & medical note
This page summarises publicly reported policy and is general information, not legal or medical advice. Ibogaine carries documented cardiac risk and remains federally controlled in the US; anyone considering it for a medical reason should consult qualified professionals and check the law in their own jurisdiction.